5-HT interaction with other neurotransmitters: An overview

Philippe De Deurwaerdere, Giuseppe Di Giovanni
Progress in Brain Research. 2021-01-01; : 1-5
DOI: 10.1016/BS.PBR.2021.01.001

Read on PubMed

1. Prog Brain Res. 2021;259:1-5. doi: 10.1016/bs.pbr.2021.01.001. Epub 2021 Jan 22.

5-HT interaction with other neurotransmitters: An overview.

De Deurwaerdere P(1), Di Giovanni G(2).

Author information:
(1)Centre National de la Recherche Scientifique, UMR CNRS 5287, Bordeaux Cedex,
France. Electronic address: .
(2)Laboratory of Neurophysiology, Department of Physiology and Biochemistry,
Faculty of Medicine and Surgery, University of Malta, Msida, Malta; Neuroscience
Division, School of Biosciences, Cardiff University, Cardiff, United Kingdom.
Electronic address: .

Serotonin (5-HT) biological functions are complex and multifaceted. It controls
almost all central nervous system (CNS) regions from cell bodies confined in the
brainstem. This means that the 5-HT system is able to interact mutually with most
neurochemical systems in the CNS. The knowledge of these interactions is
fundamental to better understand the mechanisms of action of antidepressant,
anxiolytic, antipsychotic, anti-convulsant, antiparkinsonian drugs leading to (i)
correcting the side effects of these drugs, (ii) improving the efficacy of these
drugs to enhance their beneficial response, and (iii) establishing new
therapeutic strategies for all CNS diseases including those such as Alzheimer’s
disease, epilepsy, and drug addiction which are in need of new therapeutic
approaches. The interaction of 5-HT with other neurochemical systems is specific
to that given system, and it is the ambition of this collection, comprising two
volumes to collect some authoritative reviews to highlight some of these
important interactions. The first volume covers the interaction of 5-HT and its
numerous receptors with the noradrenergic, GABAergic, endocannabinoid, and glial
cell systems. The chapters encompass vast CNS territories and show the
therapeutic relevance of targeting 5-HT/other neurotransmitter interaction for
several neuropsychiatric diseases including addiction, mood disorders, aberrant
food intake, epilepsy, and abnormal brain development.

© 2021 Elsevier B.V. All rights reserved.

DOI: 10.1016/bs.pbr.2021.01.001
PMID: 33541674 [Indexed for MEDLINE]

Know more about